Abstract
Aminoglycosides have played a major role in antimicrobial therapy since their discovery in the 1940s. Their bactericidal efficacy in gram-negative infections, synergism with beta-lactam antibiotics, limited bacterial resistance, and low cost have given these agents a firm place in antimicrobial treatment. After penicillins, aminoglycosides are the most commonly used drugs in the neonatal intensive care unit. While the pharmacodynamic action on the bacterial target is obviously the same in neonates as compared to children and adults, dramatic differences exist in terms of pharmacokinetics. Renal function is the most important determinant in respect to the elimination of aminoglycosides and, depending on the age and development of the newborn infant, dramatic changes in renal clearing capacity have been documented. The incorporation of this knowledge about the developing kidney has, very recently, resulted in a revised aminoglycoside dosing guideline for use in newborn infants. This article will therefore address the rationale behind this new dosing regimen and also explain why this has resulted in clinically important changes in how to perform therapeutic drug monitoring of aminoglycosides in neonates to ensure safe and effective use of these frequently used medicines in this vulnerable population.
Keywords: Aminoglycosides, neonates, pharmacokinetics, therapeutic drug monitoring, antimicrobial therapy, developing kidney, polycationic drugs, minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC)
Current Pharmaceutical Design
Title:Pharmacokinetics of Aminoglycosides in the Newborn
Volume: 18 Issue: 21
Author(s): Johannes N. van den Anker and Karel Allegaert
Affiliation:
Keywords: Aminoglycosides, neonates, pharmacokinetics, therapeutic drug monitoring, antimicrobial therapy, developing kidney, polycationic drugs, minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC)
Abstract: Aminoglycosides have played a major role in antimicrobial therapy since their discovery in the 1940s. Their bactericidal efficacy in gram-negative infections, synergism with beta-lactam antibiotics, limited bacterial resistance, and low cost have given these agents a firm place in antimicrobial treatment. After penicillins, aminoglycosides are the most commonly used drugs in the neonatal intensive care unit. While the pharmacodynamic action on the bacterial target is obviously the same in neonates as compared to children and adults, dramatic differences exist in terms of pharmacokinetics. Renal function is the most important determinant in respect to the elimination of aminoglycosides and, depending on the age and development of the newborn infant, dramatic changes in renal clearing capacity have been documented. The incorporation of this knowledge about the developing kidney has, very recently, resulted in a revised aminoglycoside dosing guideline for use in newborn infants. This article will therefore address the rationale behind this new dosing regimen and also explain why this has resulted in clinically important changes in how to perform therapeutic drug monitoring of aminoglycosides in neonates to ensure safe and effective use of these frequently used medicines in this vulnerable population.
Export Options
About this article
Cite this article as:
N. van den Anker Johannes and Allegaert Karel, Pharmacokinetics of Aminoglycosides in the Newborn, Current Pharmaceutical Design 2012; 18 (21) . https://dx.doi.org/10.2174/1381612811209023114
DOI https://dx.doi.org/10.2174/1381612811209023114 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology White Matter Neuroprotection in Preterm Infants
Current Pediatric Reviews Non-steroidal Anti-inflammatory Drugs (NSAIDs) in the Management of Patent Ductus Arteriosus (PDA) in Preterm Infants and Variations in Attitude in Clinical Practice: A Flight Around the World
Current Medicinal Chemistry Heart Transplantation for Congenital Heart Disease in the First Year of Life
Current Cardiology Reviews Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Bronchopulmonary Dysplasia: An Imbalance of Inflammation
Current Respiratory Medicine Reviews Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Inhaled Nitric Oxide in Preterm Neonates with Refractory Hypoxemia Associated to Oligohydramnios
Current Drug Discovery Technologies Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials Principles and Applications of Diffuse Optical Imaging for the Brain
Current Medical Imaging Near-Infrared Spectroscopy (NIRS): A Non-Invasive In Vivo Methodology for Analysis of Brain Vascular and Metabolic Activities in Real Time in Rodents
Current Vascular Pharmacology The Role of Oxidative Stress on Necrotizing Enterocolitis in Very Low Birth Weight Infants
Current Pediatric Reviews Neonatal Ultrasound in Transport
Current Pediatric Reviews Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Sedation and Analgesia in Pediatric Intensive Care
Current Drug Targets Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology Dosing Guidelines of Aminoglycosides in Neonates: A Balance Between Physiology and Feasibility
Current Pharmaceutical Design Pharmacotherapy for Patent Ductus Arteriosus: Current Options and Outstanding Questions
Current Pediatric Reviews Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry